Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
First procedures in Vietnam and Argentina extended use of Baird Medical’s microwave ablation technology into two additional markets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baird Medical (BDMD) highlighted third-quarter 2026 international expansion, regulatory registrations and a partnership adding another treatment technology to its portfolio.
In August, Pakistan’s Drug Regulatory Authority registered its BD-GT microwave ablation system and T-1610 needle, allowing their introduction in Pakistan. First procedures using its microwave ablation technology were completed in Vietnam and Argentina during the quarter. An August partnership with Alpmed focuses on global development and commercialization of irreversible electroporation, another minimally invasive treatment method. The company plans to continue market expansion, physician training and portfolio development in the fourth quarter.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointAlpmed partnership adds irreversible electroporation to the portfolio, focusing on global development and commercialization.
- Minor pointPakistan registrations for the BD-GT system and T-1610 needle allow introduction into the Pakistani market.
- Minor pointFirst microwave ablation procedures in Vietnam and Argentina extended technology use into two additional markets.
- Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter plans include continued market expansion and development of a broader minimally invasive technology portfolio.
Negative
- None.
Key Figures
- Products registered
- 2 products
- Pakistan registrations in August
- Markets with first procedures
- 2 additional markets
- Vietnam and Argentina during Q3
Historical Context
-
Agreement set global commercialization rights and planned a U.S. FDA 510(k) submission by year-end.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
irreversible electroporation medical
microwave ablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Quarter included presentation at H.C. Wainwright Global Investment Conference, strategic partnership with Alpmed, new regulatory registrations, and continued physician training
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (NASDAQ: BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership.
“During the third quarter, we continued to execute on the priorities that we believe will drive Baird Medical’s long-term growth, including extension of our geographic reach, strengthening physician adoption and broadening our technology portfolio, while continuing to share our exciting story with the investment community,” said Haimei Wu, Chairwoman and CEO of Baird Medical. “These milestones reflect the progress we are making to build a more diversified global business and create additional opportunities for growth.”
Presenting Baird Medical’s Growth Strategy at H.C. Wainwright
In September, Baird Medical participated in the H.C. Wainwright Global Investment Conference in New York, where U.S. CEO Mark Saxton and Chief Strategy Officer Daphne Huang shared details on the Company’s progress and plans for continued growth.
The presentation highlighted Baird Medical’s expanding U.S. presence, growing adoption of its microwave ablation (MWA) technology and plans to build on its established international business. Management also discussed the Company’s efforts to expand its technology portfolio and reach more physicians and patients across a broader range of markets.
“Our focus this quarter was on execution, including bringing our technology into new markets, working directly with physicians, and adding new capabilities to our portfolio,” said Mark Saxton, U.S. Chief Executive Officer of Baird Medical. “At H.C. Wainwright, we had the opportunity to share that progress with investors and discuss where we see the business going from here. The work underway across our U.S. and international operations gives us a strong foundation as we head into the final months of the year.”
Expanding the Technology Portfolio Through Alpmed Partnership
In August, Baird Medical entered into a strategic partnership with Alpmed focused on the global development and commercialization of next-generation irreversible electroporation (IRE) technology.
The partnership adds another minimally invasive treatment modality alongside Baird Medical’s existing MWA business and provides a path to introduce IRE technology across international markets. The collaboration is part of the Company’s effort to build a broader portfolio of technologies for physicians performing minimally invasive procedures.
Advancing Regulatory and Commercial Expansion in International Markets
Baird Medical also made progress expanding the availability of its MWA technology in new markets during the quarter.
In August, the Company received registrations from the Drug Regulatory Authority of Pakistan (DRAP) for its BD-GT microwave ablation system and T-1610 microwave ablation needle. The registrations allow Baird Medical to bring these products to the Pakistani market and represent another step in the Company’s international expansion.
The Company also marked the completion of first procedures using its MWA technology in Vietnam and Argentina during the quarter, extending the use of its technology into two additional markets.
Connecting with Physicians at Global Medical Conferences
Baird Medical continued its engagement with the international medical community during Q3 through participation in major industry meetings, including the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress and the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR) Annual Scientific Meeting.
These meetings provided opportunities for the Baird Medical team to connect directly with interventional radiologists and other specialists from around the world, exchange clinical experience, present the Company's technology in live settings, and discuss developments in minimally invasive treatment.
Expanding Hands-On Physician Training
Physician education remained an important area of focus during the quarter, with Baird Medical supporting training programs in both the U.S. and China.
In the U.S., the Company supported hands-on MWA training in New Orleans, where participating physicians observed procedures and gained practical experience with MWA techniques and applications.
In China, Baird Medical hosted a four-day MWA Master Class for Vietnamese physicians at The Eighth Affiliated Hospital of Sun Yat-sen University, combining clinical observation and hands-on training across multiple MWA applications.
Looking Ahead
As Baird Medical enters the fourth quarter of 2026, the Company remains focused on expanding its presence in key markets, supporting physician education and training, and advancing a broader portfolio of minimally invasive treatment technologies.
The Company expects to continue building on the clinical, commercial, and strategic progress achieved during the third quarter as it works to bring its technologies to more physicians and patients worldwide.
About Baird Medical
Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.
Baird Medical's MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which Baird Medical products received regulatory registrations in Pakistan?
Pakistan’s Drug Regulatory Authority registered Baird Medical’s BD-GT microwave ablation system and T-1610 microwave ablation needle in August 2026. These registrations allow the company to bring both products to the Pakistani market.
What does Baird Medical’s partnership with Alpmed cover?
The August 2026 partnership focuses on the global development and commercialization of irreversible electroporation technology. It adds another minimally invasive treatment method alongside Baird Medical’s existing microwave ablation business and provides a path to introduce the technology across international markets.